Automatic and standardized surgical reporting for central nervous system tumors

Magnetic resonance (MR) imaging is essential for evaluating central nervous system (CNS) tumors, guiding surgical planning, treatment decisions, and assessing postoperative outcomes and complication risks. While recent work has advanced automated tumor segmentation and report generation, most efforts have focused on preoperative data, with limited attention to postoperative imaging analysis. This study introduces a comprehensive pipeline for standardized postsurtical reporting in CNS tumors. Using the Attention U-Net architecture, segmentation models were trained for the preoperative (non-enhancing) tumor core, postoperative contrast-enhancing residual tumor, and resection cavity. Additionally, MR sequence classification and tumor type identification for contrast-enhancing lesions were explored using the DenseNet architecture. The models were integrated into a reporting pipeline, following the RANO 2.0 guidelines. Training was conducted on multicentric datasets comprising 2000 to 7000 patients, using a 5-fold cross-validation. Evaluation included patient-, voxel-, and object-wise metrics, with benchmarking against the latest BraTS challenge results. The segmentation models achieved average voxel-wise Dice scores of 87%, 66%, 70%, and 77% for the tumor core, non-enhancing tumor core, contrast-enhancing residual tumor, and resection cavity, respectively. Classification models reached 99.5% balanced accuracy in MR sequence classification and 80% in tumor type classification. The pipeline presented in this study enables robust, automated segmentation, MR sequence classification, and standardized report generation aligned with RANO 2.0 guidelines, enhancing postoperative evaluation and clinical decision-making. The proposed models and methods were integrated into Raidionics, open-source software platform for CNS tumor analysis, now including a dedicated module for postsurgical analysis.

Segmentation of glioblastomas in early post-operative multi-modal MRI with deep neural networks

Extent of resection after surgery is one of the main prognostic factors for patients diagnosed with glioblastoma. To achieve this, accurate segmentation and classification of residual tumor from post-operative MR images is essential. The current standard method for estimating it is subject to high inter- and intra-rater variability, and an automated method for segmentation of residual tumor in early post-operative MRI could lead to a more accurate estimation of extent of resection. In this study, two state-of-the-art neural network architectures for pre-operative segmentation were trained for the task. The models were extensively validated on a multicenter dataset with nearly 1000 patients, from 12 hospitals in Europe and the United States. The best performance achieved was a 61\% Dice score, and the best classification performance was about 80\% balanced accuracy, with a demonstrated ability to generalize across hospitals. In addition, the segmentation performance of the best models was on par with human expert raters. The predicted segmentations can be used to accurately classify the patients into those with residual tumor, and those with gross total resection.

Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging

Molecular classification has transformed the management of brain tumors by enabling more accurate prognostication and personalized treatment. However, timely molecular diagnostic testing for patients with brain tumors is limited, complicating surgical and adjuvant treatment and obstructing clinical trial enrollment. In this study, we developed DeepGlioma, a rapid ($< 90$ seconds), artificial-intelligence-based diagnostic screening system to streamline the molecular diagnosis of diffuse gliomas. DeepGlioma is trained using a multimodal dataset that includes stimulated Raman histology (SRH); a rapid, label-free, non-consumptive, optical imaging method; and large-scale, public genomic data. In a prospective, multicenter, international testing cohort of patients with diffuse glioma ($n=153$) who underwent real-time SRH imaging, we demonstrate that DeepGlioma can predict the molecular alterations used by the World Health Organization to define the adult-type diffuse glioma taxonomy (IDH mutation, 1p19q co-deletion and ATRX mutation), achieving a mean molecular classification accuracy of $93.3\pm 1.6\%$. Our results represent how artificial intelligence and optical histology can be used to provide a rapid and scalable adjunct to wet lab methods for the molecular screening of patients with diffuse glioma.